Celanese Corporation (CE) Stock Price & Analysis
Celanese Corporation (CE) closed at USD 47.22 on Thursday, October 22, 2026, down 0.11% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 47.27; the Oct 22, 2026 session ranged USD 46.12–47.51 on volume of 1,091,004 shares. Market capitalization is $5.18B, with a 52-week range of USD 35.13–70.7 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:16 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CE.md
Key facts (CE)
- Last four reported quarters (through Jun 30, 2026): revenue $9.71B, net income -$1.17B (-12.0% margin), free cash flow $708M (SEC filings).
- 1 of 80 tracked superinvestors hold CE (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Insider open-market purchases, last ~7 months: 3 Form 4 filings, $230K; 1 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.39 on a 1–5 scale) (18 analysts), mean target USD 61.17 (range 46–86).
- Total return with dividends: 1Y +11.8% vs S&P 500 +14.9%; 5Y -69.8% vs S&P 500 +80.3%.
- Next earnings: 2026-11-02, EPS estimate USD 1.56, revenue estimate $2.62B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CE)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $8.54B | $9.67B | $10.9B | $10.3B | $9.54B | $9.71B |
| Gross profit | $2.68B | $2.38B | $2.58B | $2.34B | $1.95B | — |
| Operating income | $1.95B | $1.38B | $1.67B | -$720M | -$786M | -$692M |
| Net income | $1.89B | $1.89B | $1.94B | -$1.54B | -$1.17B | -$1.17B |
| EPS (diluted) | $16.86 | $17.34 | $17.76 | -$14.11 | -$10.64 | — |
| Free cash flow | $1.29B | $1.28B | $1.33B | $531M | $803M | $708M |
| Gross margin | 31.4% | 24.6% | 23.6% | 22.8% | 20.5% | — |
| Operating margin | 22.8% | 14.2% | 15.2% | -7.0% | -8.2% | -7.1% |
| Net margin | 22.1% | 19.6% | 17.8% | -15.0% | -12.2% | -12.0% |
| Revenue growth | +51.0% | +13.3% | +13.0% | -6.0% | -7.1% | — |
| Cash + short-term investments | $546M | — | — | $962M | $1.26B | — |
| Total debt | $3.97B | $14.7B | $14.8B | $14.0B | $13.8B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CE)
P/S 0.5x · EV/EBITDA 119.9x · EV/Sales 1.8x · P/FCF 7.3x · P/B 1.2x · FCF yield 13.66% · Earnings yield -22.56% · Dividend yield (paid, TTM) 0.25% · Net debt $12.0B · EV $17.1B
P/E at fiscal year-ends: Dec 2023 8.7x.
Superinvestors (SEC 13F-HR, Q2 2026) (CE)
1 of 80 tracked investors hold CE. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Dodge & Cox Funds | Dodge & Cox | 0.37% | $703M | Reduced -0.4% |
Insider purchases (SEC Form 4, open-market, last ~7 months) (CE)
3 purchases, $230K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-14 | Kyrish Chuck | SVP & CFO | 2,300 | $105K | 45.52 | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-11 | Duffie Ashley B | SVP & GC | 600 | $27K | 45.6 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-11 | Murray Mark Christopher | SVP - Acetyls | 2,153 | $98K | 45.52 | Opportunistic (traded every year 2023–2025, no repeating month) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (CE)
Consensus Buy (mean 2.39 on a 1–5 scale), 18 analysts; mean target USD 61.17 (low 46, high 86).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | RBC Capital | Target raised | Sector Perform | $45 → $46 |
| 2026-10-13 | Barclays | Initiated | Equal-Weight | $49 |
| 2026-09-30 | Citigroup | Target lowered | Buy | $60 → $58 |
| 2026-09-11 | Keybanc | Initiated | Overweight | $57 |
| 2026-08-06 | Wells Fargo | Target lowered | Overweight | $80 → $65 |
| 2026-08-05 | BMO Capital | Target lowered | Market Perform | $57 → $54 |
| 2026-07-16 | Morgan Stanley | Target lowered | Equal-Weight | $72 → $58 |
| 2026-07-06 | BMO Capital | Target lowered | Market Perform | $80 → $57 |
| 2026-07-01 | Mizuho | Target lowered | Neutral | $65 → $55 |
| 2026-06-30 | B of A Securities | Target lowered | Buy | $72 → $63 |
Total return (dividends reinvested) (CE)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +11.8% | -69.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +11.8% | -21.3% |
| Volatility (annualized) | 51.8% | 47.0% |
| Max drawdown | -37.6% (May 2026→Aug 2026) | -77.5% (Mar 2024→Nov 2025) |
CE revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Engineered Materials | $1.45B | 52.5% | +0.3% |
| Acetyl Chain | $1.33B | 48.3% | +19.2% |
| Total revenue | $2.75B | 100% | — |
CE revenue by region (fiscal year ended Dec 31, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $2.57B | 26.9% | -6.1% |
| Switzerland | $2.47B | 25.9% | +740.1% |
| China | $1.79B | 18.8% | -9.7% |
| Germany | $750.0M | 7.9% | -65.9% |
| Singapore | $707.0M | 7.4% | -29.4% |
| Japan | $290.0M | 3.0% | +4.3% |
| Mexico | $243.0M | 2.5% | -29.4% |
| Other Foreign Countries | $212.0M | 2.2% | -54.7% |
| India | $148.0M | 1.6% | -4.5% |
| Brazil | $127.0M | 1.3% | -9.3% |
| South Korea | $127.0M | 1.3% | -9.3% |
| Canada | $108.0M | 1.1% | -15.0% |
| Belgium | $2.0M | 0.0% | -99.5% |
| Total revenue | $9.54B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
CE suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Fairway Methanol | “We have a joint venture, Fairway Methanol LLC ("Fairway"), with Mitsui, in which we own a 50% interest, for the production of methanol at our integrated chemical plant in Clear Lake, Texas.” |
| Partner | China National Tobacco | “China National Tobacco Corporation, a Chinese state-owned tobacco entity, has been our venture partner for over three decades.” |
| Partner | LANXESS AG (LNXSY) | “DuBay Polymer GmbH is a manufacturing joint venture with Lanxess AG for the production of PBT-based products.” |
Quoted from the company's 10-K filed Feb 24, 2026.
CE company outlook (results filed Aug 4, 2026)
- “Together with our productivity, portfolio, and footprint actions, these initiatives position Celanese to deliver strong performance in 2026 and create additional earnings growth opportunities in the years ahead," Richardson concluded. 4 Reconciliations of forecasted non-GAAP measures such as adjusted earnings per share, adjusted EBIT, operating EBITDA or free cash flow to the equivalent U.S.”
Quoted word-for-word from the SEC 8-K results press release.
CE analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.56 | $1.77 | -11.5% | $2.62B | 17 |
| Next quarter (ends Dec 2026) | $1.16 | $1.21 | -4.4% | $2.33B | 17 |
| Current fiscal year (ends Dec 2026) | $6.00 | $6.05 | -0.8% | $10.01B | 18 |
| Next fiscal year (ends Dec 2027) | $6.03 | $6.42 | -6.2% | $9.94B | 17 |
CE options: expected move
Options price a move of about ±13.9% (±$6.55) by Nov 20, 2026, which includes earnings on Nov 2, 2026. Over the last 8 reports the stock moved ±12.1% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 61.2% | ±13.9% |
| Dec 18, 2026 | 56 | 53.7% | ±16.9% |
| Jan 15, 2027 | 84 | 48.1% | ±18.5% |
| Mar 19, 2027 | 147 | 53.2% | ±26.5% |
| Jun 17, 2027 | 237 | 54.7% | ±34.1% |
| Sep 17, 2027 | 329 | 50.3% | ±36.8% |
30-day implied volatility 59.3% vs 36.7% realized over the last 30 trading days. Put/call ratio (volume) 0.2. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:16 UTC)
| Price | USD 47.22 |
|---|---|
| Change | ▼ 0.11% (down) |
| Previous Close | USD 47.27 |
| Open | USD 47.22 |
| Day Range | USD 46.12 – 47.51 |
| 52-Week Range | USD 35.13 – 70.7 |
| Volume | 1,091,004 shares |
| Market Cap | $5.18B |
| Exchange | NYQ |
Technical Analysis (CE)
Nexqual's technical model rates CE "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:16 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58.72 (neutral) |
| vs SMA50 | Above (USD 45.67) |
| MACD | 0.46 (positive) |
Analyst Ratings (CE)
Wall Street analysts rate CE "Buy" based on 18 analysts, with a mean price target of USD 61.17 (range USD 46–86), per Nexqual as of October 23, 2026 at 09:16 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 18 |
| Mean Target | USD 61.17 |
| High Target | USD 86 |
| Low Target | USD 46 |
| Buy / Hold / Sell | 10 / 8 / 0 |
Earnings (CE)
| Next Earnings Date | 2026-11-02 |
|---|---|
| EPS Estimate | USD 1.56 |
| Revenue Estimate | $2.62B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.45 vs est 2.22 ▲ beat |
| 2026-03-31 | USD 0.85 vs est 0.9 ▼ miss |
| 2025-12-31 | USD 0.67 vs est 0.91 ▼ miss |
| 2025-09-30 | USD 1.34 vs est 1.22 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Financials & Fundamentals (CE)
| Total Revenue | $9.71B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +8.70% |
| Gross Margin | +21.38% |
| Operating Margin | +11.05% |
| Profit Margin | -12.04% |
| ROE | -22.25% |
| Debt / Equity | 2.7 |
| Current Ratio | 1.45 |
| Total Cash | $1.36B |
| Total Debt | $12.40B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $708.00M (7.3% of revenue) |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Financial Health Score (CE)
Nexqual rates Celanese Corporation's overall financial health "Weak" across five dimensions, as of October 23, 2026 at 09:16 UTC.
| Growth | Weak — Revenue -7% YoY (annual), declining |
|---|---|
| Profitability | Mixed — Gross margin 21%, operating 11% (last 12 months) |
| Balance Sheet | Weak — $1.36B cash and investments vs $13.3B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $708M (last 4 quarters to Jun 2026, SEC), 7% margin |
| Efficiency | Critical — ROE -22%, ROA 2.6% |
Ownership (CE)
| Insider Ownership | +0.36% |
|---|---|
| Institutional Ownership | +112.41% |
| Shares Outstanding | 109.75M |
| Float | 99.80M |
| Short % of Float | +9.17% |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Leadership (CE)
Celanese Corporation is led by Scott A. Richardson, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:16 UTC.
| President, CEO & Director | Scott A. Richardson |
|---|---|
| Senior VP & CFO | Chuck B. Kyrish |
| Senior Vice President of Engineered Materials | Todd L. Elliott |
| Vice President of Investor Relations | William Cunningham |
| Senior Vice President Global Manufacturing | Mike Barnes |
Major Backers & Investors (CE)
Notable institutional backers of Celanese Corporation include Dodge & Cox Inc., NORGES BANK, Capital Group, according to Nexqual as of October 23, 2026 at 09:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 13.92% |
| NORGES BANK | 8.51% |
| Capital Group | 6.2% |
| SmallCap World Fund Inc | 5.75% |
| Fuller & Thaler Asset Management Inc. | 3.21% |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 2.48% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.18% |
| Vanguard Group | 10.48% |
| State Street | 3.66% |
| Dimensional Fund Advisors | 3.17% |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
From Celanese Corporation's Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Our products enjoy leading global positions due to our differentiated business models, large global production capacity, operating efficiencies, proprietary technology and competitive cost structures.
- With decades of experience, advanced proprietary process technology and favorable capital and production costs, we are a leading global producer of acetic acid, VAM and VAE.
- Our differentiated capabilities are highlighted in our intimate and unique customer engagement which allows us to work across the entirety of our customers' value chain.
- Our unique approach is based on deep customer engagement to develop new projects that are aligned with our skill domains to address critical customer needs and ensure our success and growth.
Partnerships
- Our VAntage®2 technology enables us to increase VAM capacity to meet growing customer demand globally with minimal investment.
Legal & Regulatory Risks (Item 1A, quoted)
- Failure to comply with applicable laws or regulations and/or changes in applicable laws or regulations may adversely affect our business and financial results as a whole.
- Our business exposes us to potential product liability, warranty, and tort claims, and recalls, which could adversely affect our financial condition and performance.
- Environmental regulations and other obligations relating to environmental matters could subject us to liability for clean-ups, fines, penalties and other damages, require us to incur significant costs to modify our operations and increase our manufacturing and delivery costs.
- Changes in environmental, health and safety regulations in the jurisdictions where we manufacture or sell our products could lead to a decrease in demand for or significant restrictions on use and/or production of our products and raw materials.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MEOH | Methanex Corporation | USD 60.74 | ▼ 3.8% |
| OLN | Olin Corporation | USD 15.54 | ▲ 4.09% |
| HUN | Huntsman Corporation | USD 8.72 | ▲ 5.95% |
| REX | REX American Resources Corporat | USD 39.82 | ▼ 2.4% |
| DOW | Dow Inc. | USD 31.81 | ▲ 4.71% |
| GPRE | Green Plains, Inc. | USD 13.91 | ▼ 1.77% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:16 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt